Celltrion Enters Race For Ocrevus Biosimilar, Files Omalizumab In Europe

Roche’s Ocrevus Brought In Sales Of CHF6bn In 2022, Including CHF4.5bn In US

 
• By Dean Rudge
  
Race (Panther Media GmbH/Alamy Stock Photo)
• Source: Shutterstock (Panther Media GmbH / Alamy Stock/Alamy Stock Photo)
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products